

## SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9989)

### VOLUNTARY ANNOUNCEMENT

## THE COMPANY'S H SHARES WILL BE NEWLY INCLUDED IN THE FTSE GLOBAL EQUITY INDEX SERIES

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, together with its subsidiaries referred to as the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company’s H shares will be newly included in the FTSE Global Equity Index Series (“**FTSE GEIS**”) as a mid-cap index, which will become effective on December 21, 2020.

### INFORMATION ABOUT FTSE GEIS

FTSE GEIS includes over 16,000 large, mid, small, and micro cap securities across 49 developed and emerging markets globally, with a wide range of modular indexes available to target specific markets and market segments.

Shareholders and potential investors of the **Company** are advised to exercise caution when dealing in the securities of the **Company**. The inclusion of the **Company**’s H shares in the

Li Li  
Chairman

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xiang; the non-executive director of the Company is Mr. Bu Huihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junde and Mr. Wang Shaohui.